Deslorelin
Also known as: Deslorelin acetate, D-Trp6-Pro9-NEt-LHRH, D-Trp-LHRH-PEA, Somagard, Suprelorin, Ovuplant
Gonadotropin-releasing hormone (GnRH) agonist / LHRH superagonist peptide
What it is
Deslorelin is a hormonal peptide approved in veterinary medicine for fertility suppression in dogs, and studied in humans for endometriosis and early-onset puberty. It works by initially stimulating and then suppressing sex hormone production from the pituitary. Not FDA-approved for human use; approved as a veterinary implant.
The scientific side
Deslorelin is a synthetic GnRH agonist (LHRH superagonist) that initially stimulates the pituitary-gonadal axis (the "flare-up" effect), transiently increasing gonadotropin (LH, FSH) and sex steroid secretion, followed by downregulation of pituitary GnRH receptors and sustained suppression of LH, FSH, and gonadal sex steroids (testosterone, estradiol, progesterone) (PMIDs: 36165853, 36139239, 37982053). This leads to inhibition of spermatogenesis in males and suppression of ovarian follicular development and estrous cyclicity in females (PMIDs: 36139239, 37873522, 25115038). In some non-mammalian species (e.g., freshwater stingrays, guinea pigs, veiled chameleons, land tortoises), the expected suppression may not occur or may paradoxically increase testosterone (PMIDs: 36971627, 32679355, 37982053, 37173553). Deslorelin has also been conjugated to docetaxel as a targeting ligand for LHRH-receptor-expressing prostate cancer cells.
Class: Gonadotropin-releasing hormone (GnRH) agonist / LHRH superagonist peptide
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. Note: deslorelin implants (Ovuplant) have been referenced as 'approved for use in inducing ovulation in mares', but current comprehensive FDA approval…
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Reversible chemical castration / fertility suppression in male dogs Human observational
- 4.7 mg deslorelin slow-release implant in 7 male Beagle dogs suppressed testosterone to basal levels (≤0.1 ng/mL) from D28 onwards and induced azoospermia from D35–D77; effects were reversible after implant removal. PMID 36139239 Stempel et al., Animals 2022
- After 5-month treatment and implant removal in 7 male Beagles, testicular and prostatic volume and testosterone recovered; first sperm-containing ejaculates appeared between D49–D70, normospermia between D84–D133; histology at D149 showed normal spermatogenesis. PMID 36230286 Stempel et al., Animals 2022
- In 45 intact male dogs, 4.7 mg deslorelin SRI significantly reduced testicular volume and testosterone at all time points during treatment; reversibility was variable, with individual basal testosterone noted until W7 post-removal but also physiological concentrations as early as W2. PMID 37820614 Vasetska et al., Tierarztliche Praxis 2023
- Chemical castration with deslorelin implant reduced plasma LH, FSH, testosterone, and estradiol to levels similar to surgically castrated dogs; pituitary gonadotrophs remained partially GnRH-responsive at ~133 days post-implantation. PMID 36165853 Spruijt et al., Reproduction in Domestic Animals 2023
- Six dogs treated chronically with deslorelin for 2–9 years for BPH, fertility control, abnormal reproductive behavior, and urinary incontinence; all remained in good health; one dog developed bladder carcinoma after 9 years of treatment. PMID 36670804 Romagnoli et al., Animals 2023
- Reversible fertility suppression / contraception in female dogs (bitches) Mixed
- 4.7 mg or 9.4 mg deslorelin implant in 10 adult bitches suppressed cyclicity in 6/10 for 1–4 years; bitches implanted in anoestrus could come into heat within 4–15 days after treatment; no behavioral or local/general side effects observed. PMID 19754533 Romagnoli et al., Reproduction in Domestic Animals 2009
- In 32 bitches treated repeatedly with 4.7 mg or 9.4 mg DA implants for a mean of 5.3 ± 3.4 years, treatment was successful (no major side effects) in 81%; minor side effects included body weight changes, behavioral changes, induced heat, coat changes, pseudocyesis, and transient urinary incontinence. PMID 34339906 Brändli et al., Theriogenology 2021
- Suprelorin 4.7 mg in prepubertal bitches (12–18 weeks) significantly extended median time to sexual maturity (377 days vs 217 days in controls); all bitches eventually reached puberty before 30 months; reproductive abilities preserved. PMID 36552424 Gontier et al., Animals 2022
- Deslorelin implant for estrus induction in late anestrus (≥160 days post-heat) with removal at LH peak (P4 ≥3 ng/mL) yielded fertile estrus and pregnancies; early anestrus implantation or prolonged retention reduced fertility. PMID 40015085 Holumbiiovska et al., Theriogenology 2025
- Alopecia X (hair cycle arrest) in dogs Animal studies only
- 4.7 mg deslorelin subcutaneous implant in 20 dogs with hair cycle arrest: hair regrowth in 12/16 (75%) intact males within 3 months; no hair regrowth in neutered females; no adverse effects noted. PMID 25066263 Albanese et al., Veterinary Dermatology 2014
- Single 4.7 mg deslorelin acetate implant in two intact male keeshonden with hair cycle arrest resulted in profuse hair regrowth within 3.5 months, enduring for at least 14 months. PMID 29757666 Layne & Richmond, JAAHA 2018
- First reported use in a neutered female Pomeranian: profuse hair regrowth occurred 9 months after first 4.7 mg deslorelin acetate implant; treatment considered uncomplicated, cost-effective, and safe. PMID 40271097 Coimbra & Vieira, Brazilian J Vet Med 2025
- Endometriosis-related pelvic pain (human) Human RCT
- In a randomized multicenter open-label trial, daily intranasal deslorelin with low-dose transdermal or intranasal estradiol ± testosterone add-back for 6 months significantly reduced endometriosis symptom/sign scores (baseline avg 7.4 to 2.5 at 3 months); BMD changes and hot flashes were minimal; no endometrial hyperpl PMID 26881208 Agarwal et al., BioMed Research International 2015
- Central precocious puberty (human) Human RCT
- In 29 children with central precocious puberty, deslorelin sc at 4 µg/kg/day suppressed gonadotropins, linear growth velocity, and skeletal maturation; dose of 1 µg/kg/day resulted in less LH suppression than 4 µg/kg/day. PMID 1898743 Pescovitz et al., J Clin Endocrinol Metab 1991
- In a double-blind RCT in 43 short-statured children with normally timed puberty, deslorelin 4 µg/kg/day sc for 4 years increased predicted adult height by 7.6 cm vs baseline and 10.3 cm vs placebo (p<0.005). PMID 8077329 Municchi et al., J Clin Endocrinol Metab 1993
- Prostate cancer (targeted drug conjugate, preclinical) In vitro only
- Deslorelin-docetaxel conjugate showed 15-fold greater antiproliferative potency than docetaxel alone in LNCaP and PC-3 cell lines at 72h; ~5-fold greater apoptosis; ~5.5-fold greater tumor growth inhibition in PC-3 xenograft mouse model. Efficacy was LHRH-receptor mediated. PMID 19509261 Sundaram et al., Molecular Cancer Therapeutics 2009
- Ovulation induction in mares Animal studies only
- Deslorelin implants induced ovulation in mares but were associated with prolonged interovulatory intervals, especially when followed by prostaglandin treatment; removal of implant 48h after administration resulted in normal interovulatory intervals. PMID 12212887 McCue et al., Theriogenology 2002
- Deslorelin-induced ovulation mares had longer interovulatory intervals (25.6±2.6 days vs 22.9±1.8 days in controls) and lower FSH concentrations on days 5–14 post-ovulation, with reduced pituitary responsiveness to GnRH. PMID 11280410 Farquhar et al., JAVMA 2001
- Double ovulation induction in mares (embryo transfer) Animal studies only
- 100 µg deslorelin acetate IM every 12h in mares with ≥2 follicles induced double ovulation in 82% of treated estrous cycles; embryo recovery was 1.12 vs 0.57 per cycle in treated vs control mares (p<0.05). PMID 23182475 Nagao et al., Animal Reproduction Science 2012
- Reproductive suppression in cats (tomcats and queens) Mixed
- 4.7 mg deslorelin implant in 154 intact male cats: testosterone success rate (≤0.10 ng/mL) was 77.9% at D45, 83.1% at D93, 84.4% at D186 and D279, 61.7% at D372; significant reduction in sexual behaviors, testicular volume, and penile spine score for 12 months; no relevant safety concerns. PMID 36766268 Amaral et al., Animals 2023
- 9.4 mg deslorelin implant in 14 female cats: average duration of action 790±155 days (range 525–1140); no clinically relevant side effects; significant body weight gain during treatment; reversible at end of treatment. PMID 39467341 Baldan et al., Theriogenology 2025
- In 16 queens with 4.7 mg deslorelin implant removed at 3, 6, or 9 months, resumption of ovarian function occurred 3–7 weeks post-removal; interval was longer during decreasing photoperiod. PMID 34610192 Ferré-Dolcet et al., Reproduction in Domestic Animals 2022
- Reproductive suppression in birds (pigeons, quail, cockatiels, cranes) Animal studies only
- 4.7 mg deslorelin implant IM in domestic pigeons significantly reduced LH and egg production in females for at least 49 days; efficacy on male fertility and duration in both sexes required further study. PMID 25115038 Cowan et al., J Avian Med Surg 2014
- 4.7 mg deslorelin implant SC in 8 female cockatiels significantly reduced plasma triglycerides, total cholesterol, IDL, and HDL at 1 month; progesterone concentrations were lower in deslorelin group; effects on lipids persisted up to 2 months. PMID 41926275 Sosa-Higareda et al., J Avian Med Surg 2026
- Retrospective review of 67 deslorelin implants in 13 captive cranes across 7 species: varied responses to egg suppression; some individuals continued laying ~30 days after treatment; minimal response for feather destructive behavior. PMID 42405733 Davidson & Boon, J Zoo Wildlife Med 2026
- Reproductive suppression in nonhuman primates Animal studies only
- Single 4.7 mg deslorelin implant in 6 female rhesus macaques suppressed estradiol and progesterone to basal levels within 6 days; duration varied (2 animals returned to cyclicity by days 96/113; 4 remained suppressed at 6 months). PMID 35512995 Carroll et al., JAALAS 2022
- Two 4.7 mg deslorelin implants in 4 male rhesus macaques suppressed testosterone in all subjects; time to suppression varied (26 days to ~2 months); duration of suppression varied from 70 days to at least 245 days. PMID 37844997 Tran et al., JAALAS 2023
- Reproductive suppression in zoo/exotic mammals (oryx, baboon, goat, grey mouse lemur) Animal studies only
- Deslorelin 14.1 mg or 9.4 mg SC in Oryx dammah males: fecal androgens increased up to 15 days then decreased to basal by day 150; no births recorded during treatment; contraceptive effect hypothesized up to ~10 months post-implant. PMID 32247215 Bonacina et al., Theriogenology 2020
- 4.7 mg deslorelin implant in one male olive baboon induced transient azoospermia; fertility resumed post-treatment; decreased proxies of aggressiveness and sexual arousal observed. PMID 32524631 Martinez et al., J Med Primatol 2020
- Pilot PK study in 3 female goats with single 9.4 mg SC deslorelin implant: average Cmax 83 ng/mL, Tmax 1.3h, plateau from 30–360 days; fecal estrogen and progestagen reflected anovulatory status in all goats. PMID 41065688 Rooney et al., J Zoo Wildlife Med 2025
- Reproductive suppression — species where deslorelin is ineffective Animal studies only
- 4.7 mg deslorelin implant SC in male guinea pigs failed to suppress testosterone or spermatogenesis; deslorelin proved ineffective in this species. PMID 32679355 Glocova et al., Theriogenology 2020
- Deslorelin 4.7 mg and 9.4 mg implants in male freshwater stingrays caused sustained, very high plasma testosterone (increased significantly after implantation, never returning to initial values for at least 13 months); no reduction in spermatogenesis; implants caused continuous stimulation rather than downregulation. PMID 36971627 Sailler et al., J Zoo Wildlife Med 2023
- GnRH agonist deslorelin implants in 7 female veiled chameleons did not prevent spontaneous reproductive activity in any female over 3 years of monitoring; GnRH agonist implants not appropriate for controlling reproduction in this species. PMID 37982053 Cermakova et al., Veterinarni Medicina 2023
- Single 4.7 mg deslorelin implant in 10 male Hermann's and Greek tortoises: median serum testosterone not significantly different from controls at any of 4 sampling time points over 5 months; no effect on testosterone circulation. PMID 37173553 Pisu et al., Veterinary Research Communications 2023
- Urinary incontinence (post-spaying) in dogs and cats Animal studies only
- Deslorelin acetate implant in a 2-year-old ovariectomized Norwegian Forest cat with post-spaying urinary sphincter mechanism incompetence: urinary continence restored ~25 days after implantation, maintained for at least 15 months without negative treatment-related effects. PMID 23873046 Pisu & Veronesi, J Feline Med Surg 2014
- Deslorelin used chronically in a spayed bitch for urinary incontinence; treatment was effective over the monitoring period (2–9 years across cases). PMID 36670804 Romagnoli et al., Animals 2023
- Benign prostatic hyperplasia (BPH) in male dogs Animal studies only
- Deslorelin acetate (Suprelorin) significantly affected canine ejaculate properties including leading to azoospermia; decreased libido observed; compared favorably to osaterone acetate for BPH management. PMID 35739884 Nižański et al., Animals 2022
- Deslorelin used chronically (2–9 years) in dogs for BPH control among other indications; all animals in good health during treatment. PMID 36670804 Romagnoli et al., Animals 2023
- Sexual attractiveness suppression in neutered male dogs Human RCT
- Double-blind RCT: 4.7 mg deslorelin implant in 15 neutered male dogs attracted to other males reduced attractiveness in 11/15 vs 5/15 placebo; overall treatment effect OR=5.47 (p=0.017); LH suppressed to basal levels in deslorelin group but FSH remained elevated in both groups. PMID 42119283 Leber et al., Theriogenology 2026
- Pharmacokinetics and degradation pathways In vitro only
- Deslorelin degradation in human airway epithelial cell line (Calu-1) was 8.5x faster in cytosolic fraction than membrane fraction; initially cleaved at the 3–4 bond, possibly by metalloendopeptidase and/or ACE; EDTA and captopril inhibited degradation. PMID 12751634 Koushik et al., Pharmaceutical Research 2003
- Novel LC-MS/MS assay for deslorelin in serum validated with LOD 0.03 ng/mL; in goats with 9.4 mg SC implant, Cmax avg 83 ng/mL, Tmax 1.3h, plateau from 30–360 days. PMID 41065688 Rooney et al., J Zoo Wildlife Med 2025
Protocol
Deslorelin is an approved clinical compound used medically, not as a research peptide. For medical use, see a doctor.
All studies (38)
- PMID 1898743 Human RCT
Central precocious puberty (human) - PMID 8077329 Human RCT
Central precocious puberty (human) - PMID 26881208 Human RCT
Endometriosis-related pelvic pain (human) - PMID 42119283 Human RCT
Sexual attractiveness suppression in neutered male dogs - PMID 36139239 Human observational
Reversible chemical castration / fertility suppression in male dogs - PMID 36165853 Human observational
Reversible chemical castration / fertility suppression in male dogs - PMID 36230286 Human observational
Reversible chemical castration / fertility suppression in male dogs - PMID 36670804 Human observational
Reversible chemical castration / fertility suppression in male dogs - PMID 37820614 Human observational
Reversible chemical castration / fertility suppression in male dogs - PMID 19754533 Mixed
Reversible fertility suppression / contraception in female dogs (bitches) - PMID 34339906 Mixed
Reversible fertility suppression / contraception in female dogs (bitches) - PMID 34610192 Mixed
Reproductive suppression in cats (tomcats and queens) - PMID 36552424 Mixed
Reversible fertility suppression / contraception in female dogs (bitches) - PMID 36766268 Mixed
Reproductive suppression in cats (tomcats and queens) - PMID 39467341 Mixed
Reproductive suppression in cats (tomcats and queens) - PMID 40015085 Mixed
Reversible fertility suppression / contraception in female dogs (bitches) - PMID 11280410 Animal studies only
Ovulation induction in mares - PMID 12212887 Animal studies only
Ovulation induction in mares - PMID 12751634 In vitro only
Pharmacokinetics and degradation pathways - PMID 19509261 In vitro only
Prostate cancer (targeted drug conjugate, preclinical) - PMID 23182475 Animal studies only
Double ovulation induction in mares (embryo transfer) - PMID 23873046 Animal studies only
Urinary incontinence (post-spaying) in dogs and cats - PMID 25066263 Animal studies only
Alopecia X (hair cycle arrest) in dogs - PMID 25115038 Animal studies only
Reproductive suppression in birds (pigeons, quail, cockatiels, cranes) - PMID 29757666 Animal studies only
Alopecia X (hair cycle arrest) in dogs - PMID 32247215 Animal studies only
Reproductive suppression in zoo/exotic mammals (oryx, baboon, goat, grey mouse lemur) - PMID 32524631 Animal studies only
Reproductive suppression in zoo/exotic mammals (oryx, baboon, goat, grey mouse lemur) - PMID 32679355 Animal studies only
Reproductive suppression — species where deslorelin is ineffective - PMID 35512995 Animal studies only
Reproductive suppression in nonhuman primates - PMID 35739884 Animal studies only
Benign prostatic hyperplasia (BPH) in male dogs - PMID 36971627 Animal studies only
Reproductive suppression — species where deslorelin is ineffective - PMID 37173553 Animal studies only
Reproductive suppression — species where deslorelin is ineffective - PMID 37844997 Animal studies only
Reproductive suppression in nonhuman primates - PMID 37982053 Animal studies only
Reproductive suppression — species where deslorelin is ineffective - PMID 40271097 Animal studies only
Alopecia X (hair cycle arrest) in dogs - PMID 41065688 Animal studies only
Reproductive suppression in zoo/exotic mammals (oryx, baboon, goat, grey mouse lemur) - PMID 41926275 Animal studies only
Reproductive suppression in birds (pigeons, quail, cockatiels, cranes) - PMID 42405733 Animal studies only
Reproductive suppression in birds (pigeons, quail, cockatiels, cranes)